Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers.
Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.
Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.
Location: United States, Virginia, Charlottesville
Employees: 11-50
Phone: +1 434-297-1000
Total raised: $160M
Founded date: 1996
Investors 4
| Date | Name | Website |
| - | Western Te... | westerntec... |
| - | PBM Capita... | pbmcap.com |
| - | RA Capital... | racap.com |
| - | K2 HealthV... | k2hv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.07.2021 | - | $160M | - |
Mentions in press and media 8
| Date | Title | Description |
| 12.03.2024 | Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days | CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatm... |
| 11.03.2024 | Neurological Biomarkers Market 2024 Global Analysis: Insights, Size, Share |Athena Diagnostics, Psynova Neurotech | Neurological Biomarkers Market Neurological biomarkers are detectable substances majorly found in the cerebrospinal (CSF) fluid when there has been some damage to the brain. BURLINGAME, CALIFORNIA , UNITED STATES, March 11, 2024 /EINPresswi... |
| 20.02.2024 | Health | Inside the plan to diagnose Alzheimer’s in people with no memory problems — and who stands to benefit | Melody Petersen | Los Angeles Times (TNS) In a darkened Amsterdam conference hall this summer, a panel of industry and academic scientists took the stage to announce a plan to radically expand the definition of Alzheimer’s disease to includ... |
| 13.11.2023 | Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures | - |
| 13.11.2023 | Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures | Provides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes $30 million drawn down at loan closing CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals,... |
| 01.07.2021 | All in on amyloid, Acumen Pharma’s IPO raises $160M for Alzheimer’s drug R&D | Acumen Pharmaceuticals is developing an Alzheimer’s disease drug that it believes offers advantages compared to other approaches—including the recently approved Biogen therapy. A small clinical trial is underway to potentially demonstrate t... |
| 23.05.2013 | After a restructure and an axed Merck deal, Acumen gains $20M for novel Alzheimer’s drug | They found that soluble oligomers they called amyloid beta-derived diffusible ligands, or ADDLs, were toxic to neurons and proposed that ADDLs were important to the cause of Alzheimer’s disease. That was controversial at the time, Goure sai... |
| - | After a restructure and an axed Merck deal, Acumen gains $20M for novel Alzheimer’s drug | It’s been 17 years in the making, but Acumen Pharmaceuticals hasn’t given up hope for its approach to a disease-modifying drug for Alzheimer’s disease. After restructuring to become a virtual biotech and raising a $20 million Series A, Acum... |